Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) and keeps the price target at $25.
May 21, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on SAB Biotherapeutics and keeps the price target at $25.
The reaffirmation of a Buy rating and a $25 price target by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100